



## Aastrom to Present at the Cowen 31st Annual Healthcare Conference

ANN ARBOR, Mich., March 4, 2011 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), a leading developer of expanded autologous cellular therapies for the treatment of severe, chronic cardiovascular diseases, today announced that company president and CEO Tim Mayleben will speak at the Cowen 31<sup>st</sup> Annual Healthcare Conference, which is being held March 7-9, 2011, at the Boston Marriott Copley Place in Boston.

The Aastrom presentation will take place at 4 P.M. on Monday, March 7, 2011. The presentation will be webcast live and will also be accessible in archive until 11:59 P.M. (ET) on June 5, 2011, beginning one hour after the presentation. The URL for live and archived access to the presentation is <http://www.wsw.com/webcast/cowen3/astrm/>. Participants should allow approximately five to ten minutes prior to the presentation start time to visit the site and download any streaming media software needed to listen to the webcast.

### About Aastrom Biosciences

Aastrom Biosciences is developing expanded autologous cellular therapies for use in the treatment of severe, chronic cardiovascular diseases. The company's proprietary cell-processing technology enables the manufacture of mixed-cell therapies expanded from a patient's own bone marrow and delivered directly to damaged tissues. Aastrom has advanced its cell therapies into late-stage clinical development, including a planned Phase 3 clinical program for the treatment of patients with critical limb ischemia and two ongoing Phase 2 clinical trials in patients with dilated cardiomyopathy. For more information, please visit Aastrom's website at [www.aastrom.com](http://www.aastrom.com).

The Aastrom Biosciences, Inc. logo is available at <http://www.globenewswire.com/newsroom/prs/?pkgid=3663>

*This document contains forward-looking statements, including, without limitation, statements concerning clinical trial plans and progress, objectives and expectations, clinical activity timing, intended product development, the performance and contribution of certain individuals and expected timing of collecting and analyzing treatment data, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as "anticipates," "intends," "estimates," "plans," "expects," "we believe," "we intend," and similar words or phrases, or future or conditional verbs such as "will," "would," "should," "potential," "could," "may," or similar expressions. Actual results may differ significantly from the expectations contained in the forward-looking statements. Among the factors that may result in differences are the inherent uncertainties associated with clinical trial and product development activities, regulatory approval requirements, competitive developments, and the availability of resources and the allocation of resources among different potential uses. These and other significant factors are discussed in greater detail in Aastrom's Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. These forward looking statements reflect management's current views and Aastrom does not undertake to update any of these forward-looking statements to reflect a change in its views or events or circumstances that occur after the date of this release except as required by law.*

CONTACT: Media and investor contact

Bill Berry

Berry & Company

212 253-8881

[ir@aastrom.com](mailto:ir@aastrom.com)

[bberry@berrypr.com](mailto:bberry@berrypr.com)